We translate science into treatment
We are a full-service Clinical Research Organisation with an in-house site network
CTC stands out by its in-house Site Network. It consists of six state-of-the-art research clinics across Sweden, including a FIH unit at Uppsala University Hospital, as well as a seventh clinic in Groningen, the Netherlands.
We provide full-service management and conduct of Phase 0, FIH, Phase I and Phase II studies as well as medical device investigations. Our site network supports clinical trials in all phases of development. With a flexible and innovative mindset, we offer a streamlined, cost-effective, and optimised solution customised for each trial.
Company structure
In-house Site Network for Phase 0 to Phase IV studies
Medical and Scientific Advice from pre-clinical through clinical research
60+
beds
4000+
in-patient stays
10 000+
out-patient visits
500+
clinical trials
6-8
FIH trials annually
500 000+
blood samples annually
Service portfolio
CTC’s comprehensive service portfolio is built upon our in-house expertise in Clinical Operations, DMPK & Clinical Pharmacology, Biometrics and pre- and post-market Pharmacovigilance. Additionally, our Site Network offers 6 in-house state-of-the-art research clinics strategically located across Sweden.
Special techniques
CTC is committed to advancing clinical trials through innovative methodologies and employs cutting-edge techniques that not only allows for smart trial design to address complex endpoints but also facilitate the execution of decentralised trials.
More than 100 co-workers constitute the backbone of our company
We believe that our workplace should not only be full of expertise but also of warmth, transparency, and flexibility. A place that is open for fast adaptation to new, innovative techniques. Committed to our work, we aim for high-quality deliverables that will meet our clients’ expectations.
We provide our customers with cost-effective advice, conduct and reporting of clinical trials.
Testimonials
"CTC was innovative and found a complete e-solution in our study, using everything from electronic informed consent to full tele medicine visits over the internet with the physician. Working with CTC is inspiring."
Kerstin Nilsson
CRM, BioGaia
"CTC provided us with excellent service during our FIH single ascending dose and multiple ascending dose study in volunteers and patients. CTC is flexible, service-minded and experienced."
Thomas Edlund
CEO, Betagenon
"An immense thank you to the CTC Team and its partners for this extraordinary achievement during the COVID pandemic. Special congratulations for: – The PI and Site staff for their tremendous performance with high quality deliver, – The Project Lead for her proactivity, risk-based approach, problem solving sprit and the outstanding coordination of all actors around our project to meet milestones on time – The entire project Team for huge professionalism and resilience in finding the best solutions to achieve successful project resolution and completion. High delivery with highly experienced, professional and dedicated people!"
Karine Renard
JTI
"Our pipeline consists of several candidate drugs in clinical and late preclinical development, and as a lean organization, we rely on close and effective collaborations with external partners to ensure high standards, scalability and a cost-effective development. CTC, having both scientific and operational expertise, is an ideal and highly valued partner to us. A safe and efficient advancement of candidate drugs from preclinical to initial human testing requires broad scientific knowledge, thorough operational planning and a high level of flexibility. In our collaborations, the CTC team has showed that it is possible to build in both adaptive design elements and early exploration of efficacy signals in first-in-human (FiH) protocols while maintaining a focus on trial participant safety. Effective operations and a customer-focused mindset have, together with the adaptive design elements, made the trial conduct smooth and successful. From both a scientific and operational perspective, I would highly recommend CTC as a preferred partner for FiH and other human pharmacology trials."
Elin Rosendahl
VP Clinical Development, Vicore Pharma
